Impact of Steroid-sparing Immunosuppressive Agents on Tumor Outcome in the Context of Cancer Immunotherapy with Highlight on Melanoma: a Systematic Literature Review and Meta-analysis

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Dec 31

PMID 39737191

Authors

Jennifer Strouse

Karmela Kimi Chan

Rachel Baccile

Gong He

Diana K N Louden

Mihai Giurcanu

Arohi Singh

John Rieth

Noha Abdel-Wahab

Tamiko R Katsumoto

Namrata Singh

Sherin Rouhani

Pankti Reid

Affiliations

Soon will be listed here.

Abstract

Background: The impact of steroid-sparing immunosuppressive agents (SSIAs) for immune-related adverse events (irAEs) on tumor outcome is not well-known. This systematic review evaluates tumor outcomes for corticosteroid (CS) monotherapy versus CS with SSIA (CS-SSIA) for irAE treatment with a focus on melanoma.

Methods: Search was conducted through 1/5/23 using PubMed, Embase, Cochrane CENTRAL, and Web of Science. We included case series, retrospective/prospective observational studies and interventional clinical trials. Individual-level data was analyzed using KM curves and Cox regression for overall survival (OS) and progression free survival (PFS). Time to SSIA was treated as a time-varying exposure using landmark analysis (landmark timepoint=3 months after irAE) to account for immortal time bias. For group-level data, meta-analysis compared the use of SSIA to No SSIA for irAEs.

Results: Of twenty-two publications with individual-level data, 147 patients with any cancer (57 CS, 90 CS-SSIA) and 65 with melanoma (18 CS, 47 CS-SSIA) underwent landmark analysis. Twenty-two publications underwent group-level evaluation and four were included in the meta-analysis. CS-SSIA versus CS showed higher risk of all-cause mortality and progression (HR 2.75, 95%CI: 1.44-5.27, p<0.01 and HR 1.75, 95%CI: 1.07-2.85, p=0.03, respectively). Melanoma showed worse OS and PFS for CS-SSIA versus CS (HR 5.68, 95%CI: 1.31-24.67, p=0.02 and HR 2.68, 95%CI: 1.12-6.40, p=0.03, respectively). In the meta-analysis of group-level data (n=2558), we found worse OS and PFS for CS-SSIA versus No SSIA (HR 1.58, 95%CI: 1.25; 2.01, p<0.01 and 1.70, 95%CI: 1.25-2.33, p<0.01). Tumor necrosis factor-alpha inhibitors (TNFi) were the most common SSIA. In the melanoma cohort, TNFi had worse OS and PFS versus CS (HR 6.46, 95%CI: 1.43-29.19, p = 0.02 and HR 7.49, 95%CI: 2.29-24.48, p<0.01, respectively). TNFi versus Other SSIAs showed a trend toward worse OS and worse PFS (HR 6.96, 95%CI: 0.90-53.65, p=0.06 and HR 21.5, 95%CI: 2.63-175.8, p<0.01, respectively). Meta-analysis showed a concern for TNFi compared to Other SSIA (HR 1.56, 95%CI: 1.17-2.09, p<0.01 respectively).

Conclusions: While our results raise concern about the effects of CS-SSIA and TNFi for irAE therapy on tumor outcomes, prospective randomized controlled trials are needed to definitively assess the effect of SSIAs on tumor outcomes.

References

Dearden H, Au L, Wang D, Zimmer L, Eroglu Z, Smith J . Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. Eur J Cancer. 2021; 153:168-178. DOI: 10.1016/j.ejca.2021.04.045. View

Larkin J, Chmielowski B, Lao C, Hodi F, Sharfman W, Weber J . Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis. Oncologist. 2017; 22(6):709-718. PMC: 5469590. DOI: 10.1634/theoncologist.2016-0487. View

van Not O, Verheijden R, van den Eertwegh A, Haanen J, Aarts M, van den Berkmortel F . Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. JAMA Oncol. 2022; 8(12):1794-1801. PMC: 9614679. DOI: 10.1001/jamaoncol.2022.5041. View

Kfoury M, Najean M, Lappara A, Voisin A, Champiat S, Michot J . Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias. Cancer Treat Rev. 2022; 110:102452. DOI: 10.1016/j.ctrv.2022.102452. View

Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda E . Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. J Natl Cancer Inst. 2023; 115(7):796-804. PMC: 10323889. DOI: 10.1093/jnci/djad061. View

Tomsitz D, Ruf T, Zierold S, French L, Heinzerling L . Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors. Cancers (Basel). 2023; 15(9). PMC: 10177379. DOI: 10.3390/cancers15092538. View

Hailemichael Y, Johnson D, Abdel-Wahab N, Foo W, Bentebibel S, Daher M . Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022; 40(5):509-523.e6. PMC: 9221568. DOI: 10.1016/j.ccell.2022.04.004. View

Johncilla M, Grover S, Zhang X, Jain D, Srivastava A . Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology. 2019; 76(4):531-539. DOI: 10.1111/his.14029. View

Zou F, Faleck D, Thomas A, Harris J, Satish D, Wang X . Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021; 9(11). PMC: 8601082. DOI: 10.1136/jitc-2021-003277. View

10.

Verheijden R, May A, Blank C, Aarts M, van den Berkmortel F, van den Eertwegh A . Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1-Treated Patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res. 2020; 26(9):2268-2274. DOI: 10.1158/1078-0432.CCR-19-3322. View

11.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

12.

Mitchell E, Lau P, Khoo C, Liew D, Leung J, Liu B . Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. Eur J Cancer. 2018; 105:88-102. DOI: 10.1016/j.ejca.2018.09.027. View

13.

Cheung V, Gupta T, Payne M, Middleton M, Collier J, Simmons A . Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol. 2019; 10(4):364-371. PMC: 6788136. DOI: 10.1136/flgastro-2018-101146. View

14.

Camard M, Besse B, Cariou P, Massayke S, Laparra A, Noel N . Prevalence and outcome of steroid-resistant/refractory pneumonitis induced by immune checkpoint inhibitors. Respir Med Res. 2022; 82:100969. DOI: 10.1016/j.resmer.2022.100969. View

15.

Cheung V, Gupta T, Olsson-Brown A, Subramanian S, Sasson S, Heseltine J . Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. Br J Cancer. 2020; 123(2):207-215. PMC: 7374736. DOI: 10.1038/s41416-020-0882-y. View

16.

Abu-Sbeih H, Ali F, Wang X, Mallepally N, Chen E, Altan M . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019; 7(1):93. PMC: 6444537. DOI: 10.1186/s40425-019-0577-1. View

17.

Keegan A, Ricciuti B, Garden P, Cohen L, Nishihara R, Adeni A . Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer. 2020; 8(2). PMC: 7537334. DOI: 10.1136/jitc-2020-000678. View

18.

Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y . Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers (Basel). 2022; 14(4). PMC: 8870238. DOI: 10.3390/cancers14040883. View

19.

Taliansky A, Furman O, Gadot M, Urban D, Bar J, Shapira-Frumer R . Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. Support Care Cancer. 2021; 29(12):7563-7568. PMC: 8550117. DOI: 10.1007/s00520-021-06331-5. View

20.

Badran Y, Zou F, Durbin S, Dutra B, Abu-Sbeih H, Thomas A . Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. J Immunother Cancer. 2023; 11(6). PMC: 10314704. DOI: 10.1136/jitc-2023-007195. View